,uuid,title,publisher,link,providerPublishTime,type
0,ac74f0b9-e857-37cf-9300-b119277ff5b8,Nearly 40% of Adults with Alopecia Areata Taking OLUMIANTÂ® 4-mg Saw at Least 80% Scalp Hair Coverage at 52 Weeks in Lilly's Pivotal Phase 3 Studies,PR Newswire,https://finance.yahoo.com/news/nearly-40-adults-alopecia-areata-152000734.html,1648308000,STORY
1,724de464-82eb-3ef1-b787-290e37d81ad9,Majority of Patients Treated with Lebrikizumab Achieved Skin Clearance in Lilly's Pivotal Phase 3 Atopic Dermatitis Studies,PR Newswire,https://finance.yahoo.com/news/majority-patients-treated-lebrikizumab-achieved-132000655.html,1648300800,STORY
2,22d59451-657a-3311-9d00-019d0d086e29,Lilly (LLY) Gets CRL from FDA for Sintilimab in Lung Cancer,Zacks,https://finance.yahoo.com/news/lilly-lly-gets-crl-fda-154503382.html,1648223103,STORY
3,03e42ad7-2395-346d-8bc1-e5d0e4e65efd,1 Green Flag for Eli Lilly Investors in 2022 -- and 1 Red Flag,Motley Fool,https://finance.yahoo.com/m/03e42ad7-2395-346d-8bc1-e5d0e4e65efd/1-green-flag-for-eli-lilly.html,1648220400,STORY
4,9ecb3ba7-38c1-39ee-9ae1-ad076132037d,Eli Lilly Cancer Drug Developed in China Gets FDA Rejection,Motley Fool,https://finance.yahoo.com/m/9ecb3ba7-38c1-39ee-9ae1-ad076132037d/eli-lilly-cancer-drug.html,1648159211,STORY
5,c230ad34-f4ab-3184-87c7-c1e97b48dad6,"How Rivals Merck, Bristol Myers Benefit From Eli Lilly's FDA Snag",Investor's Business Daily,https://finance.yahoo.com/m/c230ad34-f4ab-3184-87c7-c1e97b48dad6/how-rivals-merck%2C-bristol.html,1648154517,STORY
6,722bd971-7bb7-38dd-9364-51f549381306,"Flying Through the Business Cycle, Fed Needs to Land the Plane (Capital Market Research) (Weekly Market Outlook)",Moody's,https://finance.yahoo.com/news/flying-business-cycle-fed-needs-192010007.html,1648149610,STORY
7,3fa26f31-39df-348e-96e8-4351cbaef40f,Pharmaceutical giant Eli Lilly drops nearly $50M to acquire Concord site for $1B plant,American City Business Journals,https://finance.yahoo.com/m/3fa26f31-39df-348e-96e8-4351cbaef40f/pharmaceutical-giant-eli.html,1648145174,STORY
